36.—(1) Regulation 45 is amended as follows.
[F1(2) After paragraph (1) insert—
“(1A) In respect of a licence holder in Great Britain, paragraph (1) is subject to regulation 45AA.”.]
[F2(3) For paragraph (2)(b) substitute—
“(b)ensuring that the quality of medicinal products handled by the licence holder is being maintained in accordance with the requirements of—
(i)in the case of a licence holder in Great Britain, the UK marketing authorisations, certificates of registration or traditional herbal registrations, and
(ii)in the case of a licence holder in Northern Ireland, the marketing authorisations, Article 126a authorisations, certificates of registration or traditional herbal registrations,
applicable to those products.”.]
Textual Amendments
F1Reg. 36(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 26(a)
F2Reg. 36(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 26(b)
Commencement Information
I1Reg. 36 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1